Orgenesis (ORGS) Competitors $1.30 -0.10 (-7.14%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends ORGS vs. CARM, MIRA, UBX, PIRS, CVKD, MEIP, SYBX, APRE, BLRX, and CYTHShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Carisma Therapeutics (CARM), MIRA Pharmaceuticals (MIRA), Unity Biotechnology (UBX), Pieris Pharmaceuticals (PIRS), Cadrenal Therapeutics (CVKD), MEI Pharma (MEIP), Synlogic (SYBX), Aprea Therapeutics (APRE), BioLineRx (BLRX), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Carisma Therapeutics MIRA Pharmaceuticals Unity Biotechnology Pieris Pharmaceuticals Cadrenal Therapeutics MEI Pharma Synlogic Aprea Therapeutics BioLineRx Cyclo Therapeutics Orgenesis (NASDAQ:ORGS) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Do analysts prefer ORGS or CARM? Carisma Therapeutics has a consensus target price of $4.94, suggesting a potential upside of 1,082.10%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43 Do institutionals & insiders believe in ORGS or CARM? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 12.6% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ORGS or CARM more profitable? Carisma Therapeutics has a net margin of -314.78% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Carisma Therapeutics -314.78%-957.20%-96.39% Does the MarketBeat Community believe in ORGS or CARM? Carisma Therapeutics received 15 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 76.19% of users gave Carisma Therapeutics an outperform vote. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesCarisma TherapeuticsOutperform Votes1676.19% Underperform Votes523.81% Which has more volatility & risk, ORGS or CARM? Orgenesis has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Which has preferable earnings & valuation, ORGS or CARM? Orgenesis has higher earnings, but lower revenue than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K9.42-$55.36MN/AN/ACarisma Therapeutics$20.27M0.86-$86.88M-$1.56-0.27 Does the media refer more to ORGS or CARM? In the previous week, Carisma Therapeutics had 5 more articles in the media than Orgenesis. MarketBeat recorded 7 mentions for Carisma Therapeutics and 2 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 beat Carisma Therapeutics' score of -0.10 indicating that Orgenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orgenesis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCarisma Therapeutics beats Orgenesis on 12 of the 17 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.24M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E RatioN/A10.5489.7417.18Price / Sales9.42195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-0.205.094.774.78Net Income-$55.36M$151.83M$120.15M$225.60M7 Day Performance27.45%-2.13%-1.92%-1.23%1 Month Performance18.18%-3.10%11.47%3.36%1 Year PerformanceN/A11.54%30.52%16.60% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$1.30-7.1%N/AN/A$6.24M$662,000.000.00150News CoverageCARMCarisma Therapeutics3.6722 of 5 stars$0.44+9.9%$4.94+1,010.4%-85.6%$18.58M$20.27M-0.2620High Trading VolumeMIRAMIRA Pharmaceuticals2.6036 of 5 stars$1.120.0%$14.00+1,150.4%+0.5%$18.54MN/A-2.002Analyst RevisionNews CoverageUBXUnity Biotechnology3.0904 of 5 stars$1.09-2.3%$8.00+631.4%-42.5%$18.43M$240,000.00-0.8460Gap DownPIRSPieris Pharmaceuticals1.2996 of 5 stars$13.60-15.7%N/A+9.7%$17.95M$42.81M-1.12140Gap DownCVKDCadrenal Therapeutics1.7091 of 5 stars$10.82-3.4%$18.00+66.4%N/A$17.95MN/A-1.684News CoverageGap UpMEIPMEI Pharma3.9163 of 5 stars$2.66-1.5%$7.00+163.2%-59.3%$17.72M$65.30M-0.39100Analyst ForecastSYBXSynlogicN/A$1.50flatN/A-53.1%$17.55M$3.37M-0.366APREAprea Therapeutics3.2009 of 5 stars$3.19-0.3%$15.50+385.9%-19.9%$17.34M$580,000.00-1.147Analyst ForecastNews CoverageBLRXBioLineRx2.3143 of 5 stars$0.21-6.6%$9.00+4,185.7%-87.8%$16.79M$21.99M-1.0240Analyst ForecastHigh Trading VolumeCYTHCyclo Therapeutics3.2001 of 5 stars$0.58+0.0%$0.95+63.8%-65.2%$16.69M$870,725.00-0.649News Coverage Related Companies and Tools Related Companies Carisma Therapeutics Alternatives MIRA Pharmaceuticals Alternatives Unity Biotechnology Alternatives Pieris Pharmaceuticals Alternatives Cadrenal Therapeutics Alternatives MEI Pharma Alternatives Synlogic Alternatives Aprea Therapeutics Alternatives BioLineRx Alternatives Cyclo Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGS Stock Alerts